Here, we report that postsynaptic density protein of 95 kDa (PSD-95), a postsynaptic density scaffolding protein, classically conceptualized as being essential for the regulation of ionotropic glutamatergic signaling at the postsynaptic membrane, plays an unanticipated and essential role in mediating the actions of hallucinogens and atypical antipsychotic drugs at 5-HT 2A and 5-HT 2C serotonergic G-proteincoupled receptors. We show that PSD-95 is crucial for normal 5-HT 2A and 5-HT 2C expression in vivo and that PSD-95 maintains normal receptor expression by promoting apical dendritic targeting and stabilizing receptor turnover in vivo. Significantly, 5-HT 2A -and 5-HT 2Cmediated downstream signaling is impaired in PSD-95 null mice, and the 5-HT 2A -mediated head-twitch response is abnormal. Furthermore, the ability of 5-HT 2A inverse agonists to normalize behavioral changes induced by glutamate receptor antagonists is abolished in the absence of PSD-95 in vivo. These results demonstrate that PSD-95, in addition to the well known role it plays in scaffolding macromolecular glutamatergic signaling complexes, profoundly modulates metabotropic 5-HT 2A and 5-HT 2C receptor function.
Introduction
Known hallucinogens include lysergic acid diethylamide (LSD)like hallucinogens such as mescaline, LSD, psilocin, and N,Ndimethyltryptamine (Nichols, 2004) and non-LSD-like hallucinogens such as salvinorin A (Roth et al., 2002) . 5-HT 2A serotonin receptors, which represent the main site of action of the LSD-type hallucinogens (Glennon et al., 1984) , are most heavily expressed in the apical dendrites and soma of pyramidal neurons in cortical layers II, III, V, and VI (Willins et al., 1997; Jakab and Goldman-Rakic, 1998) , and knockout and tissue-specific rescue studies indicate that cortical 5-HT 2A receptors are the main site of action of hallucinogens (González-Maeso et al., 2007) . Moreover, the 5-HT 2A inverse agonist property of atypical antipsychotic drugs is thought to be an essential feature of their therapeutic actions (Meltzer et al., 1989; Roth et al., 2004a; Gray and Roth, 2007) .
The closely related 5-HT 2C serotonin receptors are located primarily in choroid plexus, striatum, and hippocampus (Molineaux et al., 1989; Clemett et al., 2000; Ló pez-Gimenez et al., 2002) . 5-HT 2C receptors are unique among G-protein-coupled receptors (GPCRs) in that they are post-transcriptionally edited (Burns et al., 1997) , a process which affects constitutive activity (Niswender et al., 1999) and the efficiency of G-protein coupling in a functionally selective manner (Price and Sanders-Bush, 2000; Berg et al., 2001; Urban et al., 2007) . A number of drugs targeting 5-HT 2C receptors have been shown to be efficacious in animal models of schizophrenia, obsessive-compulsive disorder (OCD), depression, and obesity (Dunlop et al., 2005 (Dunlop et al., , 2006 Sard et al., 2005; Gray and Roth, 2007; Marquis et al., 2007) .
Previous studies by our lab and others have demonstrated that the 5-HT 2A and 5-HT 2C receptors, which are essential for the actions of atypical antipsychotic drugs and LSD-like hallucinogens (Roth et al., 2004a; González-Maeso et al., 2007; Berger et al., 2009) , can interact in vitro via a canonical type I postsynaptic density protein of 95 kDa (PSD-95)/Dlg/ZO-1 (PDZ)-binding motif (Bécamel et al., 2002 (Bécamel et al., , 2004 Xia et al., 2003a) with PSD-95, a PDZ domain-containing scaffolding protein (Chen et al., 2000; Kim et al., 2006; Nicoll et al., 2006) that is an essential regulator of ionotropic glutamatergic neuronal signaling (Migaud et al., 1998; Sheng and Kim, 2002; Ehrlich and Malinow, 2004; Schluter et al., 2006; Xu et al., 2008) . These in vitro data suggest that PSD-95 could play a critical role in regulating 5-HT 2A and 5-HT 2C receptors in neurons in vivo, tethering these receptors to the plasma membrane and regulating their trafficking and function. In this study, we show that genetic deletion of PSD-95 leads to profound alterations in 5-HT 2A and 5-HT 2C receptor targeting, expression, and signaling. We also show that these 5-HT receptor-PSD-95 interactions are essential for the normal function of the 5-HT 2A and 5-HT 2C receptors, including their abilities to mediate hallucinogen and atypical antipsychotic drug actions in vivo. Our findings provide new insights into the precise subcellular site(s) of action of hallucinogens and atypical antipsychotic drugs, as well as implicate PSD-95 as an important regulator of metabotropic 5-HT 2A and 5-HT 2C receptor function. Figure 1 . Genetic deletion of PSD-95 results in a selective loss of 5-HT 2A and 5-HT 2C receptors. A, 5-HT 2A and PSD-95 doublelabel immunochemistry in medial prefrontal cortex of PSD-95 wildtype and PSD-95 null mice shows a large reduction in 5-HT 2A receptor expression in null mice (N ϭ 3 littermate pairs). B, 5-HT 2C immunochemistry in PSD-95 wildtype and PSD-95 null striatum and hippocampus reveals that 5-HT 2C receptor expression is almost completely abolished in the absence of PSD-95 in both striatum and hippocampus (N ϭ 3 littermate pairs). C, Comparison of B max estimates for the 5-HT 2A receptor (N ϭ 4 littermate pairs) and the 5-HT 1A receptor (N ϭ 5 littermate pairs) in PSD-95 wildtype and PSD-95 null cortices. B max estimates were obtained by performing [ 3 H]-ketanserin (5-HT 2A ) and [ 3 H]-WAY100635 (5-HT 1A ) saturation binding on microdissected and homogenized cortical tissue. Quantitation showed an ϳ40% reduction in 5-HT 2A expression and no change in 5-HT 1A expression in the cortices of PSD-95 null mice. D, Comparison of B max estimates for the 5-HT 2C receptor (N ϭ 3; tissue from 3 animals was pooled for each measurement, for a total of 9 animals, all littermate pairs) and 5-HT 1A receptor (N ϭ 6 littermate pairs) in PSD-95 wildtype and PSD-95 null hippocampi. B max estimates were obtained by performing [ 3 H]mesulergine saturation binding in the presence of 100 nM spiperone to block the vast majority of 5-HT 2A receptors (5-HT 2C ) and [ 3 H]-WAY100635 saturation binding (5-HT 1A ). Quantitation showed an almost 70% reduction in 5-HT 2C expression and no change in 5-HT 1A expression in hippocampus in the absence of PSD-95. All saturation binding was analyzed using nonlinear least squares fitting. B max data are presented as means Ϯ SEM; *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001; one-tailed unpaired t test.
7.4; 10 mM MgCl 2 ; 0.1 mM EDTA). Homogenized tissue was spun for 10 min at 26,000 ϫ g (4°C) and the SBB removed. The pellet was resuspended in 1 ml of SBB and transferred to a 1.7 ml Eppendorf tube, then spun at top speed in a microcentrifuge for 5 min at 4°C. The SBB was removed, and the pellet was either used immediately for binding or stored at Ϫ80°C until use. Saturation binding assays were performed with the homogenized brain tissue and [ 3 H]-ketanserin (5-HT 2A , cortex); [ 3 H]-mesulergine plus 100 nM spiperone (5-HT 2C , hippocampus); or [ 3 H]-WAY100635 (5-HT 1A , cortex, hippocampus), then incubated in SBB for 1.5 h. The following [ 3 H] concentrations were used: 8 nM, 6 nM, 4 nM, 2 nM, 1.5 nM, 1.0 nM, 0.5 nM, 0.25 nM (5-HT 2A and 5-HT 2C ), or 2 nM, 1.2 nM, 0.8 nM, 0.4 nM, 0.2 nM, 0.1 nM, 0.05 nM, 0.025 nM (5-HT 1A ), all in duplicate for total and nonspecific (four reactions at each concentration for each brain sample in which receptor was measured). Nonspecific binding was determined by incubating the reactions with 8 M ritanserin (5-HT 2A and 5-HT 2C ) or 10 M 5-HT (5-HT 1A ). For 5-HT 2C measurements, three samples were pooled for each assay. Bradford protein assays were performed to normalize B max determinations to the amount of protein in each assay. Reactions were harvested by vacuum filtration through glass filters (3ϫ ice-cold 50 mM Tris, pH 7.4; pH 6.9 at room temperature) and counted by liquid scintillation using a Perkin-Elmer Tri-Carb 2800TR. Microsoft Excel and Graphpad Prism were used for all data analysis.
EEDQ. EEDQ (N-ethoxycarbonyl-1,2-ethoxydihydroquinolone; dissolve EEDQ in 100% ethanol, than dilute 1:3 in saline) was injected intraperitoneally at a dose of 10 mg/kg. Mice were killed at 1, 2, 3, 5, 7, and 13 d after EEDQ treatment, and the 5-HT 2A B max was measured by saturation binding. Receptor production was assumed to be a zero-order process and receptor trafficking a first-order process (Pinto and Battaglia, 1994 Quantitative reverse transcription-PCR. Trizol (Invitrogen) was used to extract RNA from microdissected cortical tissue. RNA (10 g) was treated with DNase (DNA-free; Ambion), and 2 g of the DNase-treated RNA was added to a reverse transcription (RT) reaction which was performed using the Superscript III RNase H Reverse Transcriptase kit (Invitrogen) with oligo-(dT) 12-18 primers (Invitrogen). IQ SYBR Green Supermix (Bio-Rad) was used in a 7300 RT-PCR system (Applied Biosystems) for quantitation. All steps were performed according to manufacturer's instructions.
Microarray experiment. RNA was extracted from microdissected cortical tissue using Trizol (Invitrogen). The gene chip assay was performed by the Gene Expression and Genotyping Core Facility at the Case Comprehensive Cancer Center using the Affymetrix Genechip Mouse Genome 430 2.0 Array. Data were analyzed using the Affymetrix Genechip Operating Software, version 1.4.0.036. 5-HT 2C mRNA editing. Microdissected hippocampal tissue was pooled by genotype and used to generate cDNA as described above. The following primers were used to generate a PCR fragment (containing the edited site) that was 327 base pairs in length that was then inserted into the BamHI/EcoRI sites of pcDNA3: forward primer: 5ЈAAA GGATCC TGT GCT ATT TTC AAC TGC GTC CAT CAT G 3Ј; reverse primer: 5ЈAAA GAATTC CGG CGT AGG ACG TAG ATC GTTAAG 3Ј (Du et al., 2006) . Each bacterial colony resulting from transformation of the ligation product represents a transcript. Clones were miniprepped and sequenced to determine the extent of editing for each transcript.
Cortical neuronal cultures. Cortical neurons were prepared from postnatal (P) day 0.5 mouse pups as described previously (Ahlemeyer and Baumgart-Vogt, 2005) . Briefly, cortex was microdissected in Mg 2ϩ HBSS under a dissecting microscope and incubated at 37°C for 20 min in neurobasal medium containing 0.1% papain and 0.02% BSA. The supernatant was removed and the tissue was then mechanically triturated in neurobasal medium. The supernatant was transferred to a new sterile Eppendorf, leaving the aggregates, and spun down at 200 ϫ g for 10 min.
The supernatant was discarded and the pellet resuspended in preequilibrated (to 37°C and 5% CO 2 ) neurobasal medium containing B27 supplement, antibiotics, and 0.5 mM glutamine, and plated on coverslips coated with low molecular weight poly-L-lysine. Immunochemical experiments were performed at 4 -5 DIV.
Lentiviral preparation. PSD-95 was cloned into the Flip, ubiquitin promoter, GFP, and woodchuck hepatitis virus response element (FUGW) lentiviral vector (Lois et al., 2002) by ligating a BclI-digested PSD-95 PCR fragment into the BamHI site 5Ј to the GFP (forward primer: 5Ј-AAA TGA TCA ATG GAC TGT CTC TGT ATA GTG ACA ACC-3Ј; reverse primer: 5Ј-AAA TGA TCA GAG TCT CTC TCG GGC TGG GAC CCA-3Ј). Site-directed mutagenesis was performed to mutate away the stop site that results from the BclI-BamHI ligation at the 3Ј end of PSD-95 and shift the reading frame so that PSD-95 is in frame with GFP (sense primer: 5Ј-GCC CGA GAG AGA CTC TTA TTT CCC CCG GGG GTA CCG GT-3Ј; antisense primer: 5Ј-ACC GGT ACC CCC GGG GGA AAT AAG AGT CTC TCT CGG GC-3Ј). Fugene6 (50 l Fugene6, 10 g total DNA per 10 cm plate) was used to cotransfect HEK293T cells with three plasmids [FUGW/⌬8.9 HIV-1/VSVG (vesicular stomatitis viral glycoprotein)] in a ratio of 3.3/2.5/1. Lentivirus-containing media was collected 48 h later and filtered through a 0.45 M filter to remove cellular debris. Lentivirus was aliquoted and frozen at Ϫ80°C until use. Cortical neurons were infected with 20 -50 l GFP or PSD-95 GFP lentivirus at 2 DIV. Immunochemistry was performed at 5 DIV.
MK-212-induced c-fos in hippocampus. Mice were injected intraperitoneally with 5 mg/kg MK-212 in 0.9% sterile NaCl or vehicle. Forty-five minutes later, they were perfused with 4% paraformaldehyde. Frozen sections (Bregma Ϫ1.34 mm to Bregma Ϫ2.7 mm) were thaw mounted onto frosted slides and then used for immunochemistry and subsequent c-fos quantitation.
DOI-induced head-twitch. Mice were injected intraperitoneally with 5 mg/kg of DOI [(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]. The number of head-twitches was counted and recorded in 5 min bins for the half hour period immediately after injection. A subset of the 5 mg/kg injections (N ϭ 7) were counted by two observers, one of whom was blinded to the genotype. A comparison of the results produced by the two different observers was not significantly different (data not shown). All the other head-twitch experiments were performed by one blinded observer.
8-OH-DPAT-induced hypothermia. Rectal temperature was measured using the TH-5 Thermalert Monitoring Thermometer (Physitemp Instruments) equipped with a RET-3 probe. The probe was sterilized with 70% ethanol and covered with vaseline before measuring each mouse's temperature. Mice were then injected intraperitoneally with 5 mg/kg 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin], and rectal temperature was measured again 20 min later.
Western blot. DOI or vehicle was injected intraperitoneally, with light restraint to minimize stress effects, and then mice were killed 15 min later by cervical dislocation. Microdissection was performed on ice as quickly as possible. Tissue was homogenized in 400 l of SBB plus protease and phosphatase inhibitors and 5% glycerol. Tissue was spun for 10 min at 20 -25,000 ϫ g. The supernatant, which contains the proteins of interest, was collected and a protein assay performed for quantitation. SDS was added to 25 g of protein boiled for 5 min to denature and then used for Western blots. The following antibodies were used for Western blot, all at a 1:1000 dilution: rabbit polyclonal p-ERK1/2 (9101L; Cell Signaling Technology), rabbit polyclonal ERK1/2 (9102L; Cell Signaling Technology), p-GSK3␤ (9331; Cell Signaling Technology), and rabbit monoclonal GSK3␤ (9315; Cell Signaling Technology).
Prepulse inhibition. All prepulse inhibition (PPI) experiments were performed at the Mouse Behavioral Phenotyping Laboratory Core Facility in the Neurodevelopmental Disorders Research Center at the University of North Carolina, Chapel Hill using the SR-Lab (San Diego Instruments). Briefly, mice were placed in a small, Plexiglas cylinder housed within a large sound-proofed chamber. The cylinder is seated on a piezoelectric transducer which quantifies movement-induced vibrations. The SR-Lab chamber also contains a light, fan, and loudspeaker for acoustic stimuli. Calibration of 70 dB background sound levels and prepulse acoustic stimuli was performed with a digital sound level meter (San Diego Instruments). Each session consisted of a 5 min habituation period followed by 42 trials of seven types-no stimulation, 120 dB acoustic stimulus (AS50), and five different prepulse stimuli ranging from 4 dB over back ground (PP74) to 20 dB over background (PP90). The trial types were performed in six sets of seven, with the trial type order in each set randomized. Intertrial intervals were 10 -20 s, with an average interval of 15 s. The AS50 was 40 ms long, whereas the prepulse stimulus was 20 ms long and occurred 100 ms before the onset of the startle stimulus. The sample window for measuring startle amplitude was 65 ms. The formula used to calculate percentage PPI was: ((AS50 Ϫ startle after prepulse)/ AS50) ϫ 100. Mice were injected with vehicle, phencyclidine (PCP), or antipsychotic and PCP before being placed in the PPI chamber. When treated with vehicle or PCP, mice were immediately placed in the chamber. When treating with antipsychotic, mice were injected with antipsychotic 15 min before injecting PCP, after which mice were immediately placed in the chamber. There was a 1 week washout period between treatments.
PCP-induced hyperlocomotion. Locomotion was measured in a 1 h session in an open field chamber (40 ϫ 40 ϫ 30 cm) crossed by a grid of photobeams (VersaMax system; AccuScan Instruments). The mice were injected with vehicle or SR46349B and placed in the chamber for a 20 min acclimation period, and then they were injected with vehicle or PCP, and locomotion was measured for 1 h. Mice were treated with vehicle, 6.0 mg/kg PCP, or 1.0 mg/kg SR46349B plus 6.0 mg/kg PCP. Mice were allowed a 1 week washout period between treatments. The number of photobeam breaks was counted during the 60 min trial in 5 min bins, and a total distance traveled in centimeters was calculated from the beam break counts.
Results

PSD-95 is essential for maintaining normal 5-HT 2A and 5-HT 2C receptor expression in vivo
Previous studies demonstrated that PSD-95 interacts with 5-HT 2A (Xia et al., 2003a,b; Bécamel et al., 2004) and 5-HT 2C (Bécamel et al., 2002) receptors in vitro and in vivo. Additionally, ectopic expression of PSD-95 inhibits the agonist-mediated internalization of the 5-HT 2A receptor (Xia et al., 2003a) and promotes desensitization of 5-HT 2C receptors (Gavarini et al., 2006) in vitro. Eliminating the type I PDZ ligand motif abrogates both PSD-95 binding and functional activity in vitro (Xia et al., 2003a,b) . What, if any, effect PSD-95 might have in vivo is unknown, although we predicted that PSD-95 is responsible for proper targeting and synaptic membrane stabilization of 5-HT 2A and 5-HT 2C serotonin receptors.
To test this prediction, we examined 5-HT 2A and 5-HT 2C receptor expression in PSD-95 wildtype and PSD-95 null mice. As seen in Figure 1 A, PSD-95 null mice exhibit very little apical dendritic immunofluorescence compared with PSD-95 wildtype littermate controls. We also performed saturation binding experiments with [ 3 H]-ketanserin on microdissected cortices to obtain a quantitative estimate of 5-HT 2A receptor levels in null mice (Fig.  1C ). We determined that, consistent with our immunohistochemical findings, PSD-95 null mice exhibit a significant reduction in 5-HT 2A receptor expression.
As shown in Figure 1 B, PSD-95 null animals displayed even larger decrements of striatal and hippocampal 5-HT 2C receptors as assessed by a 5-HT 2C -selective antibody. Saturation binding isotherms using [ 3 H]-mesulergine under conditions which selectively label 5-HT 2C receptors (see Materials and Methods) demonstrated a 72% reduction in 5-HT 2C receptor expression levels in the hippocampus (Fig. 1 D) .
PSD-95 regulates serotonin receptor turnover
We next examined several potential mechanisms which might account for the PSD-95-mediated modulation of 5-HT 2A and 5-HT 2C receptor expression. These included the following: (1) nonspecific effects on the serotonin system; (2) PSD-95mediated regulation of 5-HT receptor transcription and/or a generalized disruption of the machinery essential for neuronal regulation of receptors; (3) PSD-95-mediated alterations in serotonin receptor mRNA editing; and (4) alterations in serotonin receptor turnover. Each of these possibilities will be dealt with in turn.
We first examined the possibility that genetic deletion of PSD-95 leads to generalized serotonergic system dysfunction leading to a reduction in serotonin receptor levels. We examined this first possibility by measuring the expression of a related 5-HT receptor which is also highly expressed in cortex and hippocampus but lacks a PDZ-ligand motif-the 5-HT 1A receptor. As our saturation binding experiments using [ 3 H]-WAY100635 indicate, 5-HT 1A expression levels were unchanged in PSD-95 null mice in both cortex (Fig. 1C ) and hippocampus ( Fig. 1 D) . These results indicate that genetic deletion of PSD-95 does not lead to a generalized alteration in the serotonergic system.
To examine the unlikely possibility that deleting PSD-95 leads to an alteration in 5-HT receptor gene transcription, we performed quantitative RT-PCR to measure 5-HT 2A and 5-HT 2C receptor mRNA levels. We found that 5-HT 2A mRNA levels are unchanged in cortex ( Fig. 2 A) , and 5-HT 2C mRNA levels are unchanged in hippocampus ( Fig. 2 A) . To further assess the role of PSD-95 in modulating mRNA levels more broadly, or the possibility that compensatory changes in global gene expression occur in null animals and that these compensatory changes cause the observed phenotypes, we performed whole-genome microarray analysis on cDNA prepared from PSD-95 wildtype and PSD-95 null cortices. Overall, there were few differences in transcript levels, and only 28 genes (27 genes decreased, 1 gene increased) appear to be modulated greater than twofold in the absence of PSD-95-none of which are GPCRs or are expected to modulate the expression of 5-HT receptors (supplemental Table 1 , available at www.jneurosci.org as supplemental material). Thus, the whole genome microarray data are more consistent with a role for PSD-95 in post-transcriptional/post-translational regulation of 5-HT 2A and 5-HT 2C receptors.
Interestingly, 6 of the 28 genes, out of ϳ45,000 transcripts on the microarray, have previously been reported to be induced after hallucinogen administration (Table 1) (Nichols and Sanders-Bush, 2002; González-Maeso et al., 2003) . In one study of transcripts induced by 5-HT 2A agonists, only 3 of 13 transcripts shown to be changed by agonist administration were specific to hallucinogenic agonists (González-Maeso et al., 2003) . Two of these three genes, egr2 and per1, are downregulated in the absence of PSD-95 according to our microarray data, which is consistent with a possible role of PSD-95 in mediating some 5-HT 2A signaling pathways, particularly those related to hallucinogen actions.
The 5-HT 2C receptor undergoes mRNA editing which modulates its constitutive activity, G-protein coupling efficiency, and expression (Niswender et al., 1999; Price and Sanders-Bush, 2000) . It is, therefore, conceivable that changes in 5-HT 2C receptor expression are secondary to altered editing of 5-HT 2C mR-NAs. To examine this possibility, we examined RNA editing at all possible sites in PSD-95 wildtype and PSD-95 null hippocampal tissue, and we found that there is no change in the frequency of editing at any of the five sites (Fig. 2 B) . Furthermore, there is no significant change in the proportions of 14 of the 15 different isoforms detected in the PSD-95 null mice compared with PSD-95 wildtype mice (Fig. 2C,D ). An increase in PSD-95 null mice of 1 isoform out 15, the valine-serine-isoleucine (VSI) isoform, is in-consistent with a role for mRNA editing in downregulating 5-HT 2C receptors in PSD-95 null mice. These findings indicate that neither transcriptional nor posttranscriptional mechanisms (i.e., RNA editing) can account for the large effect that genetic deletion of PSD-95 has on the expression of 5-HT 2A and 5-HT 2C receptors.
Our data clearly point to the fourth prediction that PSD-95 is exerting its effect on the 5-HT 2A and 5-HT 2C receptors by regulating their turnover. Implicit in our hypothesis is that in the absence of PSD-95, 5-HT 2A and 5-HT 2C receptors will have greater access to intracellular trafficking machinery, or will enter alternative trafficking pathways, leading to higher rates of receptor turnover. To assess the rates of receptor turnover in PSD-95 wildtype and PSD-95 null animals, we took advantage of the properties of EEDQ, which binds irreversibly to 5-HT 2A receptors (surface and intracellular), occluding them from recognition by their ligands after EEDQ treatment. By treating mice with EEDQ and modeling the rate of receptor recovery over time, one can measure the rate of 5-HT 2A receptor turnover in vivo (Pinto and Battaglia, 1994) .
For these studies, we injected mice once with EEDQ (10 mg/kg), a dose that achieves ϳ90% irreversible blockade of 5-HT 2A receptors, and performed saturation binding experiments at different time points after EEDQ treatment to measure the recovery rate of 5-HT 2A receptors. If 5-HT 2A receptors in null mice have a higher rate of turnover, then the rate constant of recovery (Pinto and Battaglia, 1994) should be higher in these mice. Consistent with this prediction, the modeled receptor recovery in PSD-95 wildtype and PSD-95 null mice ( Fig. 3 A, B) showed that the rate constant, k (d Ϫ1 ), was substantially higher in null mice. These findings indicate that genetic deletion of PSD-95 accelerates 5-HT 2A receptor turnover in vivo. Attempts to perform similar studies with 5-HT 2C receptors were unsuccessful because of the exceedingly low levels of 5-HT 2C receptors expressed in PSD-95 null mice.
PSD-95 is required for the polarized sorting of 5-HT 2A receptors to pyramidal neuron apical dendrites Another important aspect of our hypothesis focuses on 5-HT 2A receptors and the prediction that PSD-95 is crucial for proper targeting to the apical dendrites. Previous studies showed that mutating the PDZ ligand motif prevents dendritic targeting of the 5-HT 2A receptor in vitro (Xia et al., 2003b) . To determine if PSD-95 is one of the PDZ-domain proteins responsible for the preferential dendritic targeting of 5-HT 2A receptors, we examined the ability of 5-HT 2A receptors to be sorted to neuronal dendrites in cortical neurons prepared from PSD-95 wildtype and PSD-95 null mice.
For these studies, we performed confocal immunofluorescent studies of mouse cortical neurons for 5-HT 2A receptors and the dendritic marker MAP2 (Caceres et al., 1984) . As Figure 4, A and  B, illustrates, neurons prepared from PSD-95 null animals exhibit significantly lower 5-HT 2A receptor expression in both the neuronal soma and dendrites-a finding consistent with our in vivo data. To examine the impact of PSD-95 on dendritic trafficking, we also calculated a 5-HT 2A receptor cell body/dendrite expression (CB/D) ratio. If dendritic targeting is impaired in PSD-95 null neurons, we predicted that the CB/D ratio should be higher in . Fifteen isoforms were detected, and 14 of them were not significantly altered in the absence of PSD-95. There is a significant increase in the proportion of the VSI isoform in PSD-95 null mouse hippocampus. All mRNA editing data are plotted as the frequency expressed as a fraction of the total, Ϯ the SEM. Normalized mRNA measurements are presented as means Ϯ SEM; *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001; one-tailed unpaired t test for the comparison of mRNA levels and one-way ANOVA followed by Newman-Keuls post hoc tests for comparison of the mRNA editing measurements. The gene previously reported to be upregulated after hallucinogen administration is ania3, a closely related isoform that differs only in the 5Ј untranslated region and a few amino acids at the C terminus.
these neurons, as impairment of 5-HT 2A trafficking to dendrites should result in a relative accumulation of receptors in the neuronal cell body. As predicted, Figure 4 B confirms that the CB/D ratio is higher in PSD-95 null neurons.
If PSD-95 is essential for 5-HT 2A expression and sorting to the dendrites, reintroduction of PSD-95 should increase receptor expression in both the neuronal soma and dendrites. Furthermore, PSD-95 re-expression should decrease the CB/D ratio, representing an increase in dendritic targeting of receptor. To assess the effect of re-expression of PSD-95 on 5-HT 2A expression and targeting, we generated PSD-95-GFP lentivirus and a control GFP lentivirus and infected cortical neuronal cultures prepared from PSD-95 null animals (Fig. 5A) . PSD-95-GFP expression led to an ϳ2-fold increase in cell body 5-HT 2A expression and an ϳ5-fold increase in dendritic 5-HT 2A expression compared with GFP expression in neurons prepared from the same PSD-95 null animals (Fig. 5B ). Furthermore, as predicted, the CB/D ratio is greatly decreased in PSD-95 null neurons expressing PSD-95-GFP compared with those expressing the control GFP (Fig. 5B ).
PSD-95 is required for 5-HT 2C signaling in vivo
Having provided strong evidence that PSD-95 profoundly regulates the expression of 5-HT 2C receptors, we next examined the consequences of knocking out PSD-95 on 5-HT 2C function in vivo. It is well established that c-fos is an immediate early gene (IEG) which is transcribed after GPCR activation (Lo and Wong, 2006) and which is useful as a general marker of neuronal activity (Chaudhuri, 1997) . To examine the consequences of genetic deletion of PSD-95 on signaling downstream of the 5-HT 2C receptor and on neural activity, we treated mice with MK-212, a 5-HT 2C -selective agonist (Thomsen et al., 2008) , and assessed induction of c-fos in the hippocampus. Significantly, we found that the number of c-fos-positive cells after MK-212 treatment was greatly reduced in PSD-95 null animals in a number of hippocampal subregions ( Fig. 6 A, B; supplemental Fig. S1 , available at www.jneurosci.org as supplemental material). Our finding that MK-212 induces the largest c-fos response in the dentate gyrus region of the hippocampus is in accordance with previous studies (Campbell and Merchant, 2003) . This reduction did not appear to be related to alterations in hippocampal morphology or volume, as cresyl violet staining does not reveal any gross abnormalities in the absence of PSD-95 (supplemental Fig. S2 , available at www.jneurosci.org as supplemental material). Furthermore, the thickness of the stained regions [in CA1-CA3, the pyramidal layer; in dentate gyrus (DG), the granular layer] was unchanged in PSD-95 null mice (supplemental Fig. S2 , available at www.jneurosci.org as supplemental material). This decrease in c-fos induction seen in all hippocampal regions measured was highly significant (Fig. 6C ) and indicates that genetic deletion of PSD-95 greatly attenuates 5-HT 2C signaling in vivo.
PSD-95 is essential for hallucinogen actions in vivo
We also predicted that the alterations in 5-HT 2A expression induced by deleting PSD-95 should lead to a reduction in hallucinogen actions in vivo. Although a number of animal models have been proposed for studying hallucinogen action in rodents (Nichols, 2004) , head-twitch behavior has been shown to be the most specific for hallucinogenic action in that nonhallucinogenic 5-HT 2A agonists such as lisuride do not induce the behavior (González-Maeso et al., 2007) . PSD-95 wildtype and PSD-95 null mice were injected with a 5 mg/kg dose of the prototypical 5-HT 2A hallucinogen 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine hydrochloride (Imamura et al., 2002) . We found that there was a large and significant decrease in DOI-induced headtwitch in PSD-95 null animals compared with PSD-95 wildtype animals (Fig. 7A ). Head twitches are virtually nonexistent in both PSD-95 wildtype and PSD-95 null animals after saline treatment (0 -2 per 30 min; data not shown). In contrast, 8-OH-DPAT, which is known to induce hypothermia via agonist action at 5-HT 1A receptors in the CNS (Martin et al., 1992) , leads to the same decrease in temperature in both PSD-95 wildtype and PSD-95 null mice (Fig. 7A) . Together, the findings suggest that PSD-95 selectively affects behaviors mediated by 5-HT 2A receptors.
Given the reduction in DOI-induced head-twitch seen in the absence of PSD-95 in vivo, we also predicted that 5-HT 2Amediated signaling would be reduced or absent in PSD-95 null mice. The 5-HT 2A receptor has been shown to signal through a large number of canonical (phospholipase C␤) and noncanonical (phospholipase A 2 , phospholipase D, etc.) pathways (Nichols, 2004) . The evidence thus far suggests that hallucinogen action is not correlated with canonical signaling pathways, since both hallucinogenic and nonhallucinogenic agonists at the 5-HT 2A receptor activate those pathways with similar potencies (Nichols, 2004) . 5-HT 2A agonists have been shown to activate ERK1/2 via a number of different mechanisms (Hershenson et al., 1995; Greene et al., 2000; Quinn et al., 2002; Göoz et al., 2006) , and 5-HT 2A agonists also lead to Akt activation (i.e., Akt phosphorylation) (Johnson-Farley et al., 2005) . Phosphorylation of Akt leads to phosphorylation of GSK3␤, which renders that protein inactive (Beaulieu et al., 2008) . Accordingly, we predicted that the induction of phospho-ERK1/2 (pERK1/2) and phospho-GSK3␤ (p-GSK3␤) after treatment with DOI (5 mg/kg) would be reduced or absent in PSD-95 null mice (Li et al., 2004; Schmid et al., 2008) . Consistent with our prediction, we found that DOI was unable to induce pERK1/2 or pGSK3␤ in PSD-95 null mice (Fig.  7B-D) . Thus, our evidence suggests that PSD-95 plays an important role in mediating 5-HT 2A downstream signaling, and its absence results in signaling and behavioral abnormalities. 
Deletion of PSD-95 renders atypical antipsychotics ineffective
It has been recently demonstrated that synaptic and behavioral measures of dopamine-mediated synaptic plasticity are also altered by genetic deletion of PSD-95 (Yao et al., 2004) . We thus hypothesized that the prototypical, gold standard atypical antipsychotic drug clozapine, whose actions are mediated via inverse agonism at 5-HT 2A and 5-HT 2C receptors (Meltzer et al., 1989; Rauser et al., 2001) and by weak D 2 /D 3 /D 4 -dopamine antagonism (Roth et al., 2004b) , would have an altered activity in PSD-95 null mice. In this regard, the PCP-induced disruption of PPI is a well accepted pharmacological model of schizophrenia (Geyer et al., 2001; Linn and Javitt, 2001) . Importantly, clozapine preferentially normalizes PCP-induced disruption of PPI in both rodents and monkeys, whereas typical antipsychotics like haloperidol have little to no effect (Geyer et al., 2001; Linn et al., 2003) . As all the published evidence suggests that 5-HT 2A receptors are important in mediating clozapine's reversal of the PCP-induced disruption of PPI (Yamada et al., 1999) , we predicted that clozapine would exhibit an altered ability to inhibit PCP-induced disruption of PPI in PSD-95 null mice.
To test this prediction, we injected littermate pairs of PSD-95 wildtype and PSD-95 null mice with vehicle, PCP, or clozapine plus PCP, followed by PPI assessment. PCP significantly disrupted PPI at all prepulse levels in PSD-95 wildtype mice and at two of the four prepulse levels in PSD-95 null mice ( Fig. 8 A; supplemental Fig. S3 , available at www.jneurosci.org as supplemental material). Clozapine normalized the PCP-induced deficit of PPI in PSD-95 wildtype mice while having no significant effect in PSD-95 null mice. As a control, we also measured startle response and found no significant effect of genotype on startle response (AS50) with and without drug treatments (supplemental Fig. S3 , available at www.jneurosci.org as supplemental material), and clozapine treatment alone had no effect on PPI compared with vehicle-treated mice (Fig. 8 B) . Thus, genetic deletion of PSD-95 abolishes the antipsychotic-like actions of clozapine.
Although the actions of clozapine in NMDA-antagonistbased psychosis models such as PCP-induced disruption of PPI are known to be 5-HT 2A -mediated, clozapine is nonetheless a pharmacologically "dirty" drug, with a high affinity for a number of other receptors (Roth et al., 2004a) . To more firmly establish that 5-HT 2A dysfunction is responsible for the abnormal antipsychotic-like efficacy seen in the aforementioned clozapine experiment, we used two selective antagonists of the 5-HT 2A receptor, M100907 and SR46349B, which have been shown to be effective in NMDA antagonist-based animal models of psychosis (Varty et al., 1999) and in clinical studies of schizophrenic patients (Meltzer et al., 2004) . If the impaired efficacy of clozapine is because of 5-HT 2A dysfunction, then 5-HT 2A antagonists should be ineffective as antipsychotics in multiple psychosis models. In this experiment, PCP significantly disrupted PPI at 4 and 8 dB in both PSD-95 wildtype and PSD-95 null mice (Fig. 8C ). As predicted, pretreatment with M100907 (0.5 mg/kg) or SR46349B (1 mg/kg) normalized PCP-induced disruption of PPI in PSD-95 wildtype mice only, having no effect in PSD-95 null mice (Fig. 8C) . To provide further evidence that antipsychotic-like efficacy medi- Figure 4 . 5-HT 2A receptor expression and dendritic targeting is attenuated in neurons prepared from PSD-95 null mice. A, Representative images of double-label immunochemistry performed on P0.5 cortical neurons of PSD-95 wildtype and PSD-95 null mice. The red arrows highlight the same dendritic process in all three images of each neuron. MAP2-positive dendrites display reduced 5-HT 2A receptor expression in the absence of PSD-95. B, Comparison of 5-HT 2A receptor expression, normalized to MAP2 expression, in cell bodies and dendrites, and CB/D expression ratio, in PSD-95 wildtype and PSD-95 null neurons. Quantitation of 5-HT 2A receptors shows that in PSD-95 null neurons, expression is dramatically reduced in both neuronal soma and dendrites. The increase in the CB/D ratio in PSD-95 null neurons suggests an impairment in dendritic targeting in the absence of PSD-95. N ϭ 3 littermate pairs, 17 neurons from each animal, for a total of 51 neurons measured per genotype. Data are presented as the mean Ϯ the SEM; *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001; one-tailed unpaired t test.
ated by 5-HT 2A receptors is impaired in the absence of PSD-95, we examined the effect of SR46349B (1 mg/kg) in another widely used animal model of psychosis, PCP-induced hyperlocomotion, which is also normalized by atypical antipsychotics such as clozapine (Gleason and Shannon, 1997; Geyer and Ellenbroek, 2003) . As expected, SR46349B (1 mg/kg) normalizes PCP-induced hyperlocomotion in PSD-95 wildtype but not PSD-95 null mice (Fig. 8 D) . Thus, our findings are very consistent in showing that the genetic deletion of PSD-95 leads to 5-HT 2A receptor dysfunction which in turn prevents atypical antipsychotics from being therapeutically efficacious in animal models of psychosis.
Discussion
The main finding of this study is that PSD-95 is essential for serotonin receptor function and hallucinogen and atypical antipsychotic actions in vivo. These findings suggest that in addition to its well known modulatory effect on ionotropic glutamatergic signaling, PSD-95 is required for normal metabotropic serotonin receptor function. We show that PSD-95, a modular PDZ domain-containing protein which scaffolds a wide range of proteins at postsynaptic clusters, is an important regulatory partner for both 5-HT 2A and 5-HT 2C receptors in vivo. In the absence of PSD-95, the 5-HT 2A receptor has accelerated receptor turnover kinetics and decreased targeting to the appropriate dendritic compartment, leading to a decrease in total receptor expression and a concomitant decrease in 5-HT 2A -mediated signaling (p-ERK1/2 and p-GSK3␤) and behaviors (e.g., head-twitch response). In the absence of PSD-95, the 5-HT 2C receptor exhibits a larger decrease in receptor protein expression and downstream signaling. Finally, we show that, in the absence of PSD-95, the prototypical atypical antipsychotic drug clozapine, as well as the selective 5-HT 2A antagonists M100907 and SR46349B, are unable to mediate their therapeutic effects in animal psychosis models.
5-HT 2C receptors, PSD-95, and psychiatric disease
There is considerable evidence that 5-HT 2C serotonin receptors regulate hippocampal function. Genetic evidence from 5-HT 2C knock-out mice shows that long-term potentiation (LTP) is impaired in the dentate gyrus in the absence of 5-HT 2C receptors (Tecott et al., 1998) . 5-HT 2C knock-out mice also exhibit defects in behaviors thought to be mediated by the dentate gyrus (Tecott et al., 1998) and are more susceptible to spontaneous and audiogenic seizures (Tecott et al., 1995) , which are known to involve limbic recruitment (Wieraszko and Seyfried, 1993; Pereira et al., 2008) .
Despite this evidence that 5-HT 2C receptors modulate neuronal function, nothing is known regarding their targeting and reg- . PSD-95 null neurons from each animal were plated in two wells, one for GFP lentiviral infection and the other for PSD-95-GFP lentiviral infection. The yellow arrows highlight dendritic 5-HT 2A receptor expression in an infected neuron. White arrows highlight 5-HT 2A receptor expression in an uninfected neuron. GFP-infected neurons display low overall 5-HT 2A expression and low dendritic targeting. In contrast, PSD-95-GFP-infected neurons display a dramatic increase in overall 5-HT 2A receptor expression and substantially more receptor appears to be targeted to the dendritic compartment, both compared with control GFP-infected neurons and compared with uninfected neurons in the same field. B, Comparison of 5-HT 2A receptor expressionincellbodiesanddendritesandtheCB/DratioinGFP-andPSD-95-GFP-infectedPSD-95 null neurons.Expressionisnormalized to GFP or PSD-95-GFP. PSD-95-GFP leads to substantial rescue of 5-HT 2A receptor expression compared with GFP-infected control neurons.PSD-95-GFPaddbackleadstoasignificantreductionintheCB/DratiocomparedwithGFP-expressingcontrolneurons,suggesting that PSD-95-GFP is rescuing dendritic targeting of 5-HT 2A receptor expression. N ϭ 3 animals for each animal/lentivirus, and 10 infected neurons from each animal/lentivirus were measured (60 neurons total). Data are presented as the meanϮthe SEM; *pϽ0.05, **p Ͻ 0.01, ***p Ͻ 0.001; one-tailed unpaired t test.
ulation of neuronal function. Our data concerning the 5-HT 2C receptor's interaction with, and regulation by, PSD-95 suggests that the 5-HT 2C receptor is present at PSD-95-enriched neuronal domains where it would be well placed to influence neuronal excitability and synaptic properties and, therefore, brain electrical activity. Although our studies focused on 5-HT 2C function in the hippocampus, the potential relevance of our findings to 5-HT 2C function in other brain regions is also of interest. The 5-HT 2C receptor has shown promise as a target in the treatment of a number of psychiatric disorders, including in particular schizophrenia and obesity, although it has been proposed that 5-HT 2C receptors may also play a role in the etiology and treatment of OCD and depression (Dunlop et al., 2005 (Dunlop et al., , 2006 Sard et al., 2005; Gray and Roth, 2007; Marquis et al., 2007) . Thus, PSD-95 may play a role in regulating 5-HT 2C function in various disease states, although further study will be needed to investigate this intriguing possibility.
Implications of PSD-95 regulation of hallucinogen action
Although it is known that hallucinogens exert their effects via activation of the 5-HT 2A receptor (Glennon et al., 1983) , the signaling processes underlying hallucinogen action are still poorly characterized. Recent evidence suggests that cortical 5-HT 2A receptors are required for hallucinogen actions, possibly by facilitating corticocortical activity (González-Maeso et al., 2007) . Our data are relevant in several respects. First, our findings are consistent with the hypothesis that hallucinogens exert their effects at cortical pyramidal neuron apical dendrites. Apical dendritic activity has been implicated as forming the neural basis for cognition and consciousness (LaBerge, 2006; Laberge and Kasevich, 2007) , and it is thought that corticocortical connections, which are primarily composed of synaptic contacts at apical dendrites (Spratling, 2002) , are important in generating and shaping the neural activity that underlies consciousness (Tononi and Edelman, 1998) . Furthermore, the primary neuro-anatomical site of expression of 5-HT 2A receptors is the apical dendrites of cortical pyramidal neurons, particularly in layer V pyramidal neurons (Willins et al., 1997; Jakab and Goldman-Rakic, 1998) . Finally, a wide range of evidence supports altered glutamatergic signaling in neocortex as playing a key role in mediating the effects of hallucinogens on consciousness (Aghajanian and Marek, 1999). Importantly, our studies demonstrate that the overall expression and apical dendritic targeting of 5-HT 2A receptors to postsynaptic densities is significantly impaired in cortical neurons prepared from PSD-95 null mice. Also, DOI is unable to in-duce p-ERK1/2 and p-GSK3␤ in PSD-95 null mice. Not surprisingly, DOIinduced head-twitch behavior, the behavioral correlate of hallucinogen action, is also reduced. Moreover, we found that the reintroduction of PSD-95 into PSD-95 null neurons rescues both the deficient expression and targeting phenotype.
Our data provide a mechanism whereby 5-HT 2A receptors can be targeted to a cortical, postsynaptic site of action and trafficked appropriately once they have arrived. In fact, our studies have provided the first candidate subcellular locus for hallucinogen action, the PSD-95-scaffolded macromolecular signaling complex of cortical neurons. Given the accumulating evidence that hallucinogenic action involves alterations in synaptic activity, our data further suggest the possibility that hallucinogens may exert their actions via PSD-95-mediated interactions with glutamatergic signaling complexes downstream of 5-HT 2A receptor activation.
Atypical antipsychotics are ineffective in the absence of PSD-95
It has been known for some time that PCP, a noncompetitive NMDA receptor antagonist, induces psychotic and "deficit" states that are nearly indistinguishable from the positive and negative symptoms of schizophrenia (Jentsch and Roth, 1999; Olney et al., 1999; Javitt, 2004) . Furthermore, clozapine and other drugs with potent 5-HT 2A inverse agonist actions ameliorate PCP-induced PPI deficits (Carlsson et al., 1999; Yamada et al., 1999; Geyer et al., 2001; Linn et al., 2003) . There is a significant decrease in DOI-induced head-twitch in PSD-95 null mice, in contrast with the magnitude of the decrease in core body temperature induced by 8-OH-DPAT, which is the same in both PSD-95 wildtype and PSD-95 null mice. B-D, Western blot and associated quantification for p-ERK1/2, ERK1/2, p-GSK3␤, and GSK3␤ 15 min after intraperitoneal injection of vehicle or DOI (N ϭ 4 -5 littermate pairs). DOI induces pERK1/2 and pGSK3␤ in wild-type, but not null, mice. For quantification, p-ERK1/2 and p-GSK3␤ were normalized to ERK1/2 and GSK3␤, respectively. Data are given as means Ϯ the SEM; *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001; one-tailed unpaired t test. Figure 8 . The antipsychotic-like efficacy of atypical antipsychotics is lost in PSD-95 null mice. At the two prepulses shown, 4 and 12 dB, PCP significantly disrupted PPI in PSD-95 wildtype and PSD-95 null mice. In PSD-95 wildtype mice, clozapine pretreatment normalized the disruption of PPI by PCP at both 4 and 12 dB (N ϭ 6 littermate pairs). In contrast, in PSD-95 null mice, clozapine had no antipsychotic-like effect. B, PPI after treatment with clozapine alone (N ϭ 6 littermate pairs). Clozapine (0.5 mg/kg) had no effect on PPI compared with vehicle. C, PPI in PSD-95 wildtype and PSD-95 null mice after injection of vehicle, 6.0 mg/kg PCP, 0.5 mg/kg M100907 plus 6.0 mg/kg PCP, or 1.0 mg/kg SR46349B plus 6.0 mg/kg PCP. PCP significantly disrupted PPI in PSD-95 wildtype and PSD-95 null mice at 4 and 8 dB (N ϭ 12). In PSD-95 wildtype mice, M100907 or SR46349B pretreatment normalized the disruption of PPI by PCP at 4 and 8 dB, whereas in PSD-95 null mice, they had no antipsychotic-like effect. D, Locomotion after vehicle, 6.0 mg/kg PCP, and 1.0 mg/kg SR46349B plus 6.0 mg/kg PCP in PSD-95 wildtype and PSD-95 null mice (N ϭ 12). SR46349B normalizes PCP-induced hyperlocomotion in PSD-95 wildtype mice only. Data are given as means Ϯ the SEM; *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001; two-way repeated-measures ANOVA followed by Bonferroni post-tests.
Finally, genetic deletion of PSD-95 or deletion of one of the PDZ domains results in abnormalities in LTP, a phenotype related to glutamatergic dysfunction (Migaud et al., 1998; Yao et al., 2004) . Together with our data, the evidence suggest that one of the key subcellular locations at which the functional interplay between 5-HT 2A receptors and glutamatergic signaling takes place is the PSD-95-scaffolded postsynaptic density.
Since, in the absence of PSD-95, glutamatergic signaling is abnormal, and 5-HT 2A receptors are mistargeted and mistrafficked, we predicted that there may be abnormalities in the ability of clozapine and selective 5-HT 2A antagonists to alleviate PCPinduced psychotic-like behaviors in mice. We found that clozapine, M100907, or SR46349B treatment, which reduced PCPinduced deficits of PPI in PSD-95 wildtype mice, was completely ineffective in PSD-95 null mice. The dramatically impaired antipsychotic-like action of the aforementioned atypical antipsychotics in the PSD-95 null mice is likely attributable to the combined abnormalities in 5-HT 2A and 5-HT 2C receptor functionboth of which have long been thought to be essential for their unique benefits (Roth et al., 2004a) . Our studies clearly implicate the 5-HT 2A dysfunction that results in the absence of PSD-95 as being responsible for the lack of atypical antipsychotic efficacy in PSD-95 null mice.
Conclusions
In this study, we demonstrate that PSD-95, in addition to its well known role in scaffolding glutamatergic signaling complexes and facilitating neuronal plasticity, potently regulates neuronal metabotropic serotonin receptor targeting, trafficking, and signaling in vivo. Furthermore, we show that the absence of PSD-95 results in abnormal downstream signaling for both 5-HT 2A receptors and 5-HT 2C receptors, both of which are important therapeutic targets for a number of psychiatric diseases. We also show that the 5-HT 2A dysfunction has profound consequences with regards to the treatment of psychotic-like states in relevant animal models. Our findings demonstrate an unexpectedly profound role for PSD-95 in regulating 5-HT 2A and 5-HT 2C receptor function and the behavioral responses to drugs acting at these receptors. These results imply that PSD-95 may serve as a scaffold to integrate information between ionotropic and metabotropic neurotransmission at postsynaptic densities.
